Human Metabolome Technologies, Inc.

Tokyo Stock Exchange 6090.T

Human Metabolome Technologies, Inc. Market Capitalization on January 14, 2025: USD 23.02 M

Human Metabolome Technologies, Inc. Market Capitalization is USD 23.02 M on January 14, 2025, a -6.77% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Human Metabolome Technologies, Inc. 52-week high Market Capitalization is USD 25.75 M on September 19, 2024, which is 11.88% above the current Market Capitalization.
  • Human Metabolome Technologies, Inc. 52-week low Market Capitalization is USD 20.94 M on August 05, 2024, which is -9.04% below the current Market Capitalization.
  • Human Metabolome Technologies, Inc. average Market Capitalization for the last 52 weeks is USD 23.65 M.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
Tokyo Stock Exchange: 6090.T

Human Metabolome Technologies, Inc.

CEO Mr. Yasuhiro Ohata
IPO Date Jan. 21, 2014
Location Japan
Headquarters 246-2 Mizukami Kakuganji
Employees 58
Sector Health Care
Industries
Description

Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.

StockViz Staff

January 16, 2025

Any question? Send us an email